Clin2
NCT07521384Possibly a fitEnrolling by invitation

Real-World Study of Intranasal Cell Therapy for Brain Injuries

Traumatic Brain InjuryCerebral PalsyHypoxic Ischemic EncephalopathyNeurologic DisordersMS (Multiple Sclerosis)Alzheimer Dementia (AD)Parkinson Disease (PD)Stroke

Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Injuries & trauma, Mental health clinical trials.

This study follows people who receive intranasal stem cell or exosome therapy (tiny packages from special cells) for brain or neurological conditions like stroke, brain injury, or cerebral palsy. Researchers track how well the treatment works by measuring inflammation markers in the blood and monitoring clinical improvements over time.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
36 people
Ages
4 years to 80 years
Study type
Observational

Who can take part

  • You have a diagnosed neurological condition such as traumatic brain injury, stroke, cerebral palsy, or similar brain disorder
  • You are receiving or have scheduled intranasal MuSE stem cell or exosome therapy as part of your medical care
  • You can have a blood test to measure inflammation before treatment and during follow-up visits
  • Your brain condition has been stable for at least 2 weeks before starting the study
  • You do not have an active infection at the time of enrollment
  • You are not taking strong immune-suppressing medications that could affect study measurements

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT02795052Recruiting
Stem cell treatment trial for nerve injury

This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.

Westport, Connecticut
NCT06146062Recruiting· Phase 2
Stem cell therapy for severe traumatic brain injury

This trial tests whether a single infusion of stem cells from donated umbilical cord tissue can help calm inflammation in the brain after severe traumatic brain injury. It is for patients aged 18–50 who need brain pressure monitoring and are not responding to verbal commands 5 days after sedation is stopped.

Clamart
NCT05158101Recruiting· Phase 1
Nasal stem cell exosome treatment safety for stroke

This early-stage study (Phase 1) tests whether a tiny dose given through the nose is safe for people who have had a stroke. It uses exosomes made from adult umbilical cord stem cells, mainly to look for side effects and dosing safety.

St John's
NCT05018832Not yet recruiting· Phase 1
Tested stem cell infusion for traumatic brain injury safety

This early study tests whether an intravenous (through a vein) stem cell treatment made from donated umbilical cord tissue is safe for people with traumatic brain injury. It focuses mainly on side effects and safety, and only includes participants who meet several health and pregnancy-related safety checks.

St John's
NCT05951777Recruiting· Phase 2
Stem cells from your own fat for chronic brain injury

This trial tests whether stem cells taken from your own fat and given through an IV can help people with long-term brain damage from a head injury. It is for adults who have not gotten better with standard treatments.

Houston, Texas
NCT07326059Not yet recruiting
MUSE stem cell therapy for traumatic brain injury study

This study looks at the safety and outcomes of MUSE stem cell therapy for people with traumatic brain injury. If you have had a TBI at least 6 months ago and are planning to receive MUSE therapy outside the U.S., you may be able to join and help researchers learn more.

Houston, Texas

Hear when a new Traumatic Brain Injury trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.